News | August 10, 2021
SMS Pharmaceuticals revenue grows by 44%; Profit up 235%
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Filing for WHO Emergency Use Authorisation this month
The company expects revenue growth of 10-15 per cent in the US
Deal for 100 million doses with additional 100 million through 2023
It is part of the company’s pain/analgesics portfolio of OTC products
The govt has rolled out three schemes for promoting the manufacture of API
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
